Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Burkitt Lymphoma 24Multiple Myeloma 20Lymphoma, Large B-Cell, Diffuse 20Leukemia, Myeloid, Acute 16Lymphoma, Non-Hodgkin 14Myelodysplastic Syndromes 13Lymphoma 13Lymphoma, Follicular 11Lymphoma, B-Cell 11Recurrence 10Ovarian Neoplasms 10Triple Negative Breast Neoplasms 9Leukemia, Lymphocytic, Chronic, B-Cell 9Hodgkin Disease 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Mantle-Cell 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia 8Breast Neoplasms 8Pancreatic Neoplasms 7Neoplasms 7Hematologic Neoplasms 7Sarcoma 6Osteosarcoma 6Colorectal Neoplasms 6Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Biphenotypic, Acute 5Graft vs Host Disease 5

Interventions

thymoglobulin 1luspatercept 1fludarabine 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
beta-Thalassemia × Cyclophosphamide × 30 days × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡